Omeros' OMS721 underwhelms in Phase II

Shares of Omeros Corp. (NASDAQ:OMER) regained some ground Tuesday a day after the stock tumbled on data from nine evaluable steroid-free patients with IgA nephropathy in a Phase II trial showing that once-weekly IV OMS721 for

Read the full 367 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE